Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if fulvestrant and abemaciclib can help
to control low-grade serous ovarian cancer. The safety of this drug combination will also be
studied.
This is an investigational study. Fulvestrant and abemaciclib are both FDA approved and
commercially available for the treatment of several types of cancer. Their use in patients
with low-grade serous ovarian cancer is investigational. The study doctor can explain how the
study drugs are designed to work.
Up to 15 participants will be enrolled in this study. All will take part at MD Anderson.